News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Shiba Inu Flags Copycat Scams After Rolling Out SOU
DailyCoin·2026/02/24 20:00
Economists Challenge Citrini's AI Doom Thesis, Call It 'Allegorical'
Finviz·2026/02/24 19:57
Here is Why ICON Public Limited Company (ICLR) Offers an Impressive Upside
Finviz·2026/02/24 19:48
Mettler-Toledo International Inc. (MTD) Navigating Through Uncertain Macro Backdrop
Finviz·2026/02/24 19:45
Top economist claims the stock market has become ‘more and more detached from the real economy’
101 finance·2026/02/24 19:42
Monero (XMR) hits resistance as bears threaten the $300 level
CryptoNewsNet·2026/02/24 19:42
Baird Maintains Outperform Rating on Charles River Laboratories International, Inc. (CRL)
Finviz·2026/02/24 19:39
Reasons Why Bruker Corporation (BRKR) Appears So Attractive
Finviz·2026/02/24 19:39
IQVIA Holdings Inc. (IQV) Offers Impressive Upside Despite AI-Linked Threats
Finviz·2026/02/24 19:36
Agilent Technologies, Inc. (A) Sparks Confidence With Latest Approvals
Finviz·2026/02/24 19:36
Flash
23:17
From the new UK fiscal year, crypto ETNs cannot be included in mainstream ISA accounts.Starting from the new fiscal year on April 6, UK investors will not be able to add crypto ETNs to their “Stocks and Shares ISA” tax-free accounts. The UK tax authority, HM Revenue and Customs (HMRC), currently classifies crypto ETNs only as assets eligible for the “Innovative Finance ISA,” and at present, no platforms plan to support such products. Investors who already hold crypto ETNs do not need to sell them, and HMRC stated it will continue to assess whether to adjust its policy.
23:10
Due to the impact of data events, Coupang, Inc.'s growth and profitability trends are expected to remain relatively flat in the coming months.This situation may place certain constraints on the company's overall performance. Although Coupang, Inc. has demonstrated strong growth momentum in the past, recent data events may cause its business expansion and profitability to face short-term pressure. Market observers are closely monitoring related developments to assess their long-term impact.
23:08
Rhythm Pharmaceuticals Inc. (referred to as Rhythm Pharmaceuticals) recently disclosed that some of its shareholders plan to further sell up to 2.4 million shares of common stock.This stock sale plan is led by existing shareholders, aiming to achieve their personal asset allocation goals. The transaction is expected to provide additional liquidity to the market, while potentially having some impact on the existing equity structure. The company emphasizes that this stock sale is a personal financial arrangement by the shareholders and does not involve the issuance of new shares by Rhythm Pharmaceuticals, so it will not have a dilutive effect on the company's total capital.